CD8A and cancer: Figure 14I illustrated that the low-risk patients appear to be insensitive to immunologic therapy. Importantly, enhanced TIS, NFAG, IFNAP, CD8A, STAT1, and SEPEN1 were clustered in the high-risk group (Figure 14C–H). These results suggested that patients in the high-risk group might be more susceptible to immunologic therapy. Notably, in the GSE91061 and GSE115821 cohorts, BMGs could also predict the effect of immunotherapy on malignant tumors (Figure 14J,K).